Clinical trial
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute…
NCT00003405 · Rush University Medical Center, Other · Withdrawn
Key facts
| NCT number | NCT00003405 |
|---|---|
| Title | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia |
| Official title | Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon |
| Lead sponsor | Rush University Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, amifostine trihydrate, bromodeoxyuridine, cytarabine, idarubicin, idoxuridine, isotretinoin, mitoxantrone hydrochloride |
| Enrollment | 0 |
| Start date | Apr 1, 1998 |
| Primary completion | Apr 1, 1999 |
| Completion | Apr 1, 1999 |
| First posted | May 24, 2004 |
| Last update posted | Oct 14, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: